89bio Inc

General ticker "ETNB" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $884.7M

89bio Inc does not follow the US Stock Market performance with the rate: -15.1%.

Estimated limits based on current volatility of 5.8%: low 7.19$, high 8.08$

Factors to consider:

  • Company does not operate outside North America (retrieved using AI)
  • Price in estimated range
  • Earnings for 9 months up through Q3 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [5.17$, 12.13$]
  • 2024-12-30 to 2025-12-30 estimated range: [3.29$, 8.14$]

Financial Metrics affecting the ETNB estimates:

  • Negative: Non-GAAP EPS, $ of -2.01 <= 0.10
  • Negative: Operating profit margin, % of -100 <= 1.03
  • Negative: negative Net income
  • Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
  • Negative: Operating cash flow per share per price, % of -15.72 <= 2.35

Similar symbols

Short-term ETNB quotes

Long-term ETNB plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $89.74MM $102.25MM $151.20MM
Operating Income $-89.74MM $-102.25MM $-151.20MM
Non-Operating Income $-0.53MM $0.24MM $12.88MM
Interest Expense $0.67MM $1.92MM $3.59MM
R&D Expense $70.33MM $80.80MM $122.23MM
Income(Loss) $-90.27MM $-102.01MM $-138.32MM
Taxes $-0.15MM $0.02MM $3.87MM
Profit(Loss) $-90.12MM $-102.03MM $-142.19MM
Stockholders Equity $125.96MM $151.83MM $536.31MM
Assets $162.42MM $196.82MM $596.27MM
Operating Cash Flow $-76.78MM $-81.09MM $-129.19MM
Capital expenditure $0.06MM $0.01MM $0.00MM
Investing Cash Flow $7.16MM $-33.94MM $-123.02MM
Financing Cash Flow $23.87MM $117.83MM $513.11MM
Earnings Per Share* $-4.48 $-2.93 $-2.00

* EPS are Split Adjusted, recent splits may be reflected with a delay.